Optimal Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherothrombosis
Status:
Recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
The Purpose of this open-label randomized controlled multicenter trial is to evaluate the
efficacy and safety of mono-drug therapy with oral anticoagulant compared to combination
therapy with antiplatelet drug, in ischemic stroke patients with non-valvular atrial
fibrillation and atherothrombosis.
Phase:
Phase 4
Details
Lead Sponsor:
National Cerebral and Cardiovascular Center National Hospital Organization Osaka National Hospital
Collaborators:
Network for Clinical Stroke Trials The BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program